Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL: 7,225 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
7,225
Total FAERS Reports
141 (2.0%)
Deaths Reported
535
Hospitalizations
7,225
As Primary/Secondary Suspect
46
Life-Threatening
34
Disabilities

Active Ingredient: EMTRICITABINE\RILPIVIRINE HYDROCHLORIDE\TENOFOVIR DISOPROXIL FUMARATE ·

First Report: 199601 · Latest Report: 20250513

What Are the Most Common EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL Side Effects?

#1 Most Reported
Bone density decreased
3,497 reports (48.4%)
#2 Most Reported
Renal injury
2,955 reports (40.9%)
#3 Most Reported
Skeletal injury
2,766 reports (38.3%)

All EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Bone density decreased 3,497 48.4% 38 156
Renal injury 2,955 40.9% 43 133
Skeletal injury 2,766 38.3% 40 127
Tooth injury 1,969 27.3% 22 82
Tooth loss 1,968 27.2% 21 91
Chronic kidney disease 1,960 27.1% 47 194
Renal failure 1,600 22.2% 47 207
Bone loss 1,530 21.2% 20 74
Osteonecrosis 1,492 20.7% 22 78
Multiple fractures 1,489 20.6% 23 80
Osteoporosis 1,415 19.6% 14 78
Pain 1,371 19.0% 14 126
Emotional distress 1,356 18.8% 14 125
Anxiety 1,251 17.3% 11 120
Anhedonia 1,207 16.7% 10 115
Osteopenia 886 12.3% 8 37
Acute kidney injury 434 6.0% 13 135
Blood creatinine increased 424 5.9% 3 34
Economic problem 403 5.6% 6 42
Vitamin d deficiency 367 5.1% 3 20

Who Reports EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL Side Effects? Age & Gender Data

Gender: 30.3% female, 69.7% male. Average age: 46.5 years. Most reports from: US. View detailed demographics →

Is EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL Getting Safer? Reports by Year

YearReportsDeathsHosp.
2000 2 1 0
2001 9 1 1
2002 14 0 0
2003 18 0 1
2004 31 1 3
2005 60 2 7
2006 68 1 11
2007 79 3 7
2008 110 2 12
2009 162 2 10
2010 245 3 17
2011 212 8 11
2012 341 3 32
2013 384 8 37
2014 529 12 49
2015 598 8 66
2016 594 8 57
2017 570 10 45
2018 534 17 30
2019 478 6 29
2020 186 2 8
2021 93 1 7
2022 42 3 3
2023 23 10 0
2024 10 0 1
2025 1 0 0

View full timeline →

What Is EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL Used For?

IndicationReports
Hiv infection 5,840
Product used for unknown indication 859
Acquired immunodeficiency syndrome 427
Prophylaxis against hiv infection 27
Antiretroviral therapy 21
Hepatitis b 21
Hiv test positive 11
Maternal exposure timing unspecified 7

EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs Alternatives: Which Is Safer?

EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs EMTRICITABINE\TENOFOVIR EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs EMTRICITABINE\TENOFOVIR ALAFENAMIDE EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs EMTRICITABINE/TENOFOVIR DISOPROXIL EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs EMTRICITABINE\TENOFOVIR DISOPROXIL EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs ENALAPRIL EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs ENALAPRIL\HYDROCHLOROTHIAZIDE EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs ENALAPRIL\LERCANIDIPINE EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs ENASIDENIB EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs ENBREL EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL vs ENCORAFENIB

Official FDA Label for EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL

Official prescribing information from the FDA-approved drug label.